Subscribe to CarissaRaman.com Subscribe to CarissaRaman.com's comments

Posts tagged ‘Parties’

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES

 

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities, nor is it calculated to invite any such offer or invitation. Neither this announcement nor any copy thereof may be taken into or distributed, directly or indirectly, in or into the United States (including its territories and dependencies, any State of the United States and the District of Columbia). In particular, this announcement does not constitute and is not an offer to sell or a solicitation of any offer to purchase or subscribe for securities in the United States or elsewhere. The securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended. Any public offering of securities to be made in the United States will only be made by means of a prospectus that may be obtained from the issuer or selling security holder and that contains detailed information about the issuer and management as well as financial statements. There is no intention to make a public offering of the securities referred to in this announcement in the United States.                                                                   


Almere, The Netherlands
April 24, 2017

ASM International N.V. (Euronext Amsterdam:ASM) (“ASMI”) announces the pricing and the generated proceeds of its partial secondary placement of shares of ASM Pacific Technology Ltd. (“ASMPT”).

ASMI has placed a total of 20,000,000 ordinary shares of ASMPT at a price of HK$ 105.00 per share to institutional and other professional investors through a partial secondary share placement representing a stake of approximately 5% in ASMPT. The offering generated cash proceeds for ASMI of a total amount of HK$ 2.1 billion (approximately €248 million). ASMI has agreed to a 180-day lock-up period.

As of today ASMI continues to be the largest shareholder in ASMPT with a stake of approximately 34%.

The Hongkong and Shanghai Banking Corporation Limited acted as bookrunner for this transaction.  

The Company intends to use the proceeds for a new share buyback program.


About ASM International

ASM International NV, headquartered in Almere, the Netherlands, its subsidiaries and participations design and manufacture equipment and materials used to produce semiconductor devices. ASM International, its subsidiaries and participations provide production solutions for wafer processing (Front-end segment) as well as for assembly packaging and surface mount technology (Back-end segment) through facilities in the United States, Europe, Japan and Asia. ASM International’s common stock trades on the Euronext Amsterdam Stock Exchange (symbol ASM). For more information, visit ASMI’s website at www.asm.com.


IMPORTANT NOTICES

The Hongkong and Shanghai Banking Corporation Limited (“HSBC”) is acting for the Company in relation to the transaction, will not regard any other person as a client in relation to the transaction and will not be responsible to anyone other than the Company for providing the protections afforded to clients of HSBC nor for providing advice to any such other person. Without prejudice to liability for fraud, HSBC, its affiliates and its and its and their respective directors, officers, employees and agents disclaim any liability to any such other person in connection with the transaction. 

This announcement is for information purposes only and, save as expressly set out herein, does not constitute an offer or invitation to underwrite, subscribe for or otherwise acquire or dispose of any securities or investment advice in any jurisdiction, including without limitation, the United Kingdom, the United States, Hong Kong, Australia, Canada, Japan, or South Africa. Persons needing advice should consult an independent financial adviser.

This announcement has been issued by and is the sole responsibility of the Company. No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by the Bookrunner or by any of its respective affiliates or agents as to or in relation to, the accuracy or completeness of this announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefor is expressly disclaimed.

The distribution of this announcement and the placing of the shares as set out in this announcement in certain jurisdictions may be restricted by law. No action has been taken by the Company or the Bookrunner that would permit an offering of such shares or possession or distribution of this announcement or any other offering or publicity material relating to such shares in any jurisdiction where action for that purpose is required.  Persons into whose possession this announcement comes are required by the Company and the Bookrunner to inform themselves about, and to observe, such restrictions.

This announcement does not constitute a prospectus or an offer or invitation to purchase securities. This announcement is only addressed to, and directed at, persons in member states of the European Economic Area (“EEA”) who are “qualified investors” within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC) as amended by the 2010 PD Amending Directive (Directive 2010/73/EU), as and to the extent implemented in the relevant EEA member state, and any relevant implementing measure in the relevant member state.

In addition, in the United Kingdom, this announcement is not being distributed, nor has it been approved for the purposes of Section 21 of the Financial Services and Markets Act 2000 (“FSMA”), by a person authorised under FSMA and is directed only at, persons (i) who are persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), or (ii) persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order, and other persons to whom it may lawfully be communicated (“relevant persons”). Under no circumstances should persons who are not relevant persons rely or act upon the contents of this announcement. Any investment or investment activity to which this announcement relates in the United Kingdom is available only to, and will be engaged only with, relevant persons.

This announcement does not constitute an invitation or offer to acquire, purchase or subscribe for securities, nor is it calculated to invite any such offer or invitation. Neither this announcement nor any copy thereof may be taken into or distributed, directly or indirectly, in or into the United States (including its territories and dependencies, any State of the United States and the District of Columbia). In particular, this announcement does not constitute and is not an offer to sell or a solicitation of any offer to purchase or subscribe for securities in the United States or elsewhere. The securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended. Any public offering of securities to be made in the United States will only be made by means of a prospectus that may be obtained from the issuer or selling security holder and that contains detailed information about the issuer and management as well as financial statements. There is no intention to make a public offering of the securities referred to in this announcement in the United States.

This announcement contains forward-looking statements. These statements are subject to a number of risks and uncertainties and actual results, and events could differ materially from those currently being anticipated as reflected in such forward-looking statements. The terms “expect”, “should be”, “will be” and similar expressions identify forward-looking statements. Factors which may cause future outcomes to differ from those foreseen in forward-looking statements include, but are not limited to: general economic and business conditions; demand for the Company’s products and services; competitive factors in the industries in which the Company operates; exchange rate fluctuations; legislative, fiscal and regulatory developments; political risks; terrorism, acts of war and pandemics; changes in law and legal interpretations affecting the Company’s intellectual property rights and internet communications; and the impact of technological change. Forward-looking statements speak only as of the date of such statements and, except as required by applicable law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. The information contained in this announcement is subject to change without notice and neither the Company nor the Bookrunner assume any responsibility or obligation to update publicly or review any of the forward-looking statements contained herein.

Any indication in this announcement of the price at which ordinary shares have been bought or sold in the past cannot be relied upon as a guide to future performance.  No statement in this announcement is intended to be a profit forecast and no statement in this announcement should be interpreted to mean that earnings per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings per share of the Company.

The Bookrunner may participate in the Placement on a proprietary basis.


CONTACT

Investor contact:

Victor Bareño

T: +31 88 100 8500

E: victor.bareno@asm.com

 
Media contact:

Ian Bickerton

T: +31 625 018 512

 

 


ASMI RAISES € 248 MIO FROM 5% STAKE SALE IN ASMPT

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: ASM International NV via Globenewswire

Article source: http://www.nasdaq.com/press-release/asm-international-nv-raises--248-million-from-5-stake-sale-in-asmpt-20170424-01024

Article source: http://www.ed.nl/economie/dejavu-events-uit-eindhoven-kleurt-amsterdam-oranje~a7eb2c46/

Having trouble signing in?

Contact Customer Support at
customer.service@haymarket.com
or check our frequently asked questions about signing in to the site.

Article source: http://www.citmagazine.com/article/1430695/hyatt-hotels-debuts-amsterdam

ING PROFILE

ING is a global financial institution with a strong European base, offering banking services through its operating company ING Bank. The purpose of ING Bank is empowering people to stay a step ahead in life and in business. ING Bank’s 52,000 employees offer retail and wholesale banking services to customers in over 40 countries.

ING Group shares are listed on the exchanges of Amsterdam (INGA AS, INGA.AS), Brussels and on the New York Stock Exchange (ADRs: ING US, ING.N).

Sustainability forms an integral part of ING’s strategy, which is evidenced by the number one position among 395 banks ranked by Sustainalytics. ING Group shares are being included in the FTSE4Good index and in the Dow Jones Sustainability Index (Europe and World) where ING is among the leaders in the Banks industry group.  

 

IMPORTANT LEGAL INFORMATION

Elements of this press release contain or may contain information about ING Groep N.V. and/ or ING Bank N.V. within the meaning of Article 7(1) to (4) of EU Regulation No 596/ 2014.

Projects may be subject to regulatory approvals. Insofar as they could have an impact in Belgium, all projects described are proposed intentions of the bank. No formal decisions will be taken until the information and consultation phases with the Work Council have been properly finalised.

Certain of the statements contained herein are not historical facts, including, without limitation, certain statements made of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Actual results, performance or events may differ materially from those in such statements due to a number of factors, including, without limitation: (1) changes in general economic conditions, in particular economic conditions in ING’s core markets, (2) changes in performance of financial markets, including developing markets, (3) potential consequences of European Union countries leaving the European Union or a break-up of the euro, (4) changes in the availability of, and costs associated with, sources of liquidity such as interbank funding, as well as conditions in the credit and capital markets generally, including changes in borrower and counterparty creditworthiness, (5) changes affecting interest rate levels, (6) changes affecting currency exchange rates, (7) changes in investor and customer behaviour, (8) changes in general competitive factors, (9) changes in laws and regulations and the interpretation and application thereof, (10) geopolitical risks and policies and actions of governmental and regulatory authorities, (11) changes in standards and interpretations under International Financial Reporting Standards (IFRS) and the application thereof, (12) conclusions with regard to purchase accounting assumptions and methodologies, and other changes in accounting assumptions and methodologies including changes in valuation of issued securities and credit market exposure, (13) changes in ownership that could affect the future availability to us of net operating loss, net capital and built-in loss carry forwards, (14) changes in credit ratings, (15) the outcome of current and future legal and regulatory proceedings, (16) ING’s ability to achieve its strategy, including projected operational synergies and cost-saving programmes and (17) the other risks and uncertainties detailed in the most recent annual report of ING Groep N.V. (including the Risk Factors contained therein) and ING’s more recent disclosures, including press releases, which are available on www.ING.com.  Many of those factors are beyond ING’s control.

Any forward looking statements made by or on behalf of ING speak only as of the date they are made, and ING assumes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information or for any other reason.

This document does not constitute an offer to sell, or a solicitation of an offer to purchase, any securities in the United States or any other jurisdiction.

Article source: https://globenewswire.com/news-release/2017/04/25/971057/0/en/ING-to-participate-in-Bank-of-Beijing-share-offering.html

Early Sunday morning: We confess to initially being less awake than the statue at the entrance to the Amsterdam convention center. Strong coffee and strong messages about hepatitis elimination quickly brought us to life.

The Sunday edition of The New York Times often includes a short feature in which a prominent person is asked to describe how he or she likes to spend an idle Sunday. Common activities are brunch, museums, outdoor activities, etc.

This came to mind yesterday as we watched more than 160 people gather for one of the final sessions of the fifty-second International Liver Congress (ILC). Whoever would have expected so many prominent people to pass on a leisurely Sunday morning in Amsterdam, after four long days of events, in favor of an 8.30 a.m. gathering titled “Elimination of hepatitis B and C in the EU: challenges and opportunities”?

The event emphasized the tremendous potential of direct-acting antiviral (DAA) treatment regimens to reduce HCV prevalence and incidence in PWID, as well as the programmatic, political and structural barriers that must be overcome to make real progress on the ground.

This session represented only one of many ways in which the European Association for the Study of the Liver (EASL) helped to foster the dialogue about public health dimensions of viral hepatitis at this year’s ILC. (Disclosure: the first author is a board member of EASL’s recently launched International Liver Foundation.)

For us, one of the highlights of the conference was a 19 April workshop jointly convened by EASL and the International Network on Hepatitis in Substance Users (INHSU). A broad range of participants discussed efforts to eliminate hepatitis C virus (HCV) in people who inject drugs (PWID) from multiple perspectives. The event emphasized the tremendous potential of direct-acting antiviral (DAA) treatment regimens to reduce HCV prevalence and incidence in PWID, as well as the programmatic, political and structural barriers that must be overcome to make real progress on the ground.

The ILC programme also included a well-attended World Health Organization (WHO) symposium on “Hepatologists as key partners in meeting the elimination goals of the WHO hepatitis strategy”. And at an abstract-driven session titled, “Public health issues in hepatology”, valuable learnings were shared from two countries with national HCV elimination programmes, Georgia and Iceland, as well as from experiences in key populations including migrants, prison inmates and PWID.

We applaud the ILC’s organisers for recognising that non-biomedical experts include not only a range of health service providers and public health practitioners but also liver patients.

Multidisciplinary approaches to liver disease were prominent at this ILC. We mean this both in the sense that the programme brought hepatologists and other types of physicians into dialogue about multidisciplinary clinical care, and also in the sense that it provided physicians and other experts with valuable opportunities to learn from each other.

It is exciting to see public health perspectives thoughtfully integrated into such a prestigious biomedical conference. And we applaud the ILC’s organisers for recognising that non-biomedical experts include not only a range of health service providers and public health practitioners but also liver patients.

Delegates from liver patient groups bring perspectives that the rest of us need to hear. Tatjana Reic, President of the European Liver Patients Association, aptly demonstrated this at the Sunday morning event on HBV/HCV elimination in the EU. Instead of referring to PWID as a “hard-to-reach” population, she remarked during her presentation, why not refer to them as an “easy-to-ignore” population?

Indeed.

We look forward to the further cross-pollination of diverse ways of thinking within EASL and at future editions of ILC.


Hepatology, Medicine and Policy is now accepting submissions on this and related issues. For more information, visit: www.hmap.biomedcentral.com.

Article source: http://blogs.biomedcentral.com/on-health/2017/04/25/elimination-at-ilc2017-make-mine-a-double-espresso-that-is/

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES

 

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities, nor is it calculated to invite any such offer or invitation. Neither this announcement nor any copy thereof may be taken into or distributed, directly or indirectly, in or into the United States (including its territories and dependencies, any State of the United States and the District of Columbia). In particular, this announcement does not constitute and is not an offer to sell or a solicitation of any offer to purchase or subscribe for securities in the United States or elsewhere. The securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended. Any public offering of securities to be made in the United States will only be made by means of a prospectus that may be obtained from the issuer or selling security holder and that contains detailed information about the issuer and management as well as financial statements. There is no intention to make a public offering of the securities referred to in this announcement in the United States.                                                                   


Almere, The Netherlands
April 24, 2017

ASM International N.V. (Euronext Amsterdam: ASM) (ASMI) announces the pricing and the generated proceeds of its partial secondary placement of shares of ASM Pacific Technology Ltd. (ASMPT).

ASMI has placed a total of 20,000,000 ordinary shares of ASMPT at a price of HK$ 105.00 per share to institutional and other professional investors through a partial secondary share placement representing a stake of approximately 5% in ASMPT. The offering generated cash proceeds for ASMI of a total amount of HK$ 2.1 billion (approximately €248 million). ASMI has agreed to a 180-day lock-up period.

As of today ASMI continues to be the largest shareholder in ASMPT with a stake of approximately 34%.

The Hongkong and Shanghai Banking Corporation Limited acted as bookrunner for this transaction.  

The Company intends to use the proceeds for a new share buyback program.


About ASM International

ASM International NV, headquartered in Almere, the Netherlands, its subsidiaries and participations design and manufacture equipment and materials used to produce semiconductor devices. ASM International, its subsidiaries and participations provide production solutions for wafer processing (Front-end segment) as well as for assembly packaging and surface mount technology (Back-end segment) through facilities in the United States, Europe, Japan and Asia. ASM International’s common stock trades on the Euronext Amsterdam Stock Exchange (symbol ASM). For more information, visit ASMI’s website at www.asm.com.


IMPORTANT NOTICES

The Hongkong and Shanghai Banking Corporation Limited (“HSBC”) is acting for the Company in relation to the transaction, will not regard any other person as a client in relation to the transaction and will not be responsible to anyone other than the Company for providing the protections afforded to clients of HSBC nor for providing advice to any such other person. Without prejudice to liability for fraud, HSBC, its affiliates and its and its and their respective directors, officers, employees and agents disclaim any liability to any such other person in connection with the transaction. 

This announcement is for information purposes only and, save as expressly set out herein, does not constitute an offer or invitation to underwrite, subscribe for or otherwise acquire or dispose of any securities or investment advice in any jurisdiction, including without limitation, the United Kingdom, the United States, Hong Kong, Australia, Canada, Japan, or South Africa. Persons needing advice should consult an independent financial adviser.

This announcement has been issued by and is the sole responsibility of the Company. No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by the Bookrunner or by any of its respective affiliates or agents as to or in relation to, the accuracy or completeness of this announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefor is expressly disclaimed.

The distribution of this announcement and the placing of the shares as set out in this announcement in certain jurisdictions may be restricted by law. No action has been taken by the Company or the Bookrunner that would permit an offering of such shares or possession or distribution of this announcement or any other offering or publicity material relating to such shares in any jurisdiction where action for that purpose is required.  Persons into whose possession this announcement comes are required by the Company and the Bookrunner to inform themselves about, and to observe, such restrictions.

This announcement does not constitute a prospectus or an offer or invitation to purchase securities. This announcement is only addressed to, and directed at, persons in member states of the European Economic Area (“EEA”) who are “qualified investors” within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC) as amended by the 2010 PD Amending Directive (Directive 2010/73/EU), as and to the extent implemented in the relevant EEA member state, and any relevant implementing measure in the relevant member state.

In addition, in the United Kingdom, this announcement is not being distributed, nor has it been approved for the purposes of Section 21 of the Financial Services and Markets Act 2000 (“FSMA”), by a person authorised under FSMA and is directed only at, persons (i) who are persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), or (ii) persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order, and other persons to whom it may lawfully be communicated (“relevant persons”). Under no circumstances should persons who are not relevant persons rely or act upon the contents of this announcement. Any investment or investment activity to which this announcement relates in the United Kingdom is available only to, and will be engaged only with, relevant persons.

This announcement does not constitute an invitation or offer to acquire, purchase or subscribe for securities, nor is it calculated to invite any such offer or invitation. Neither this announcement nor any copy thereof may be taken into or distributed, directly or indirectly, in or into the United States (including its territories and dependencies, any State of the United States and the District of Columbia). In particular, this announcement does not constitute and is not an offer to sell or a solicitation of any offer to purchase or subscribe for securities in the United States or elsewhere. The securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended. Any public offering of securities to be made in the United States will only be made by means of a prospectus that may be obtained from the issuer or selling security holder and that contains detailed information about the issuer and management as well as financial statements. There is no intention to make a public offering of the securities referred to in this announcement in the United States.

This announcement contains forward-looking statements. These statements are subject to a number of risks and uncertainties and actual results, and events could differ materially from those currently being anticipated as reflected in such forward-looking statements. The terms “expect”, “should be”, “will be” and similar expressions identify forward-looking statements. Factors which may cause future outcomes to differ from those foreseen in forward-looking statements include, but are not limited to: general economic and business conditions; demand for the Company’s products and services; competitive factors in the industries in which the Company operates; exchange rate fluctuations; legislative, fiscal and regulatory developments; political risks; terrorism, acts of war and pandemics; changes in law and legal interpretations affecting the Company’s intellectual property rights and internet communications; and the impact of technological change. Forward-looking statements speak only as of the date of such statements and, except as required by applicable law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. The information contained in this announcement is subject to change without notice and neither the Company nor the Bookrunner assume any responsibility or obligation to update publicly or review any of the forward-looking statements contained herein.

Any indication in this announcement of the price at which ordinary shares have been bought or sold in the past cannot be relied upon as a guide to future performance.  No statement in this announcement is intended to be a profit forecast and no statement in this announcement should be interpreted to mean that earnings per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings per share of the Company.

The Bookrunner may participate in the Placement on a proprietary basis.


CONTACT

Investor contact:

Victor Bareño

T: +31 88 100 8500

E: victor.bareno@asm.com

 
Media contact:

Ian Bickerton

T: +31 625 018 512

 

 


Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/c8224679-1443-4a0a-b299-bd5f9f661baf

Article source: https://globenewswire.com/news-release/2017/04/24/970449/0/en/ASM-INTERNATIONAL-N-V-RAISES-248-MILLION-FROM-5-STAKE-SALE-IN-ASMPT.html

Our favorites

Article source: http://www.deephouseamsterdam.com/movement-sonus-festival-join-forces-summer-event/

‘)})();
//–

Aviation Daily

WASHINGTON—The Dutch Safety Board (DSB) is calling on the Dutch Ministry of Infrastructure and the Environment to determine who in the government should have “final responsibility” for the safety of air traffic at and around Amsterdam Airport Schiphol.

The request is one of eight recommendations included in a final report capping a yearlong investigation into an increase in runway incursions and other on-airport incidents since 2014.

While the DSB said it had found “no evidence to suggest that safety at Schiphol is inadequate,” officials did find many opportunities for improvement. Those include the need for a central authority with final responsibility. “The ministry has no overall picture of aviation safety at and around Schiphol, nor is it able to determine whether the main safety objectives are being achieved,” the DSB said. “In addition, the Human Environment and Transport Inspectorate lacks the knowledge and resources required to maintain effective in-depth oversight of the parties operating at Schiphol.”

The DSB launched the probe in March 2016, after seeing “a series of incidents, some of which occurred more than once” at the airport starting in 2014, and coincident with an increase in traffic. The agency’s goal was to determine if the problems were due to multiple root problems, including layout, location and how operators are using the facility.

“Schiphol is a complex airport, both in terms of its infrastructure and in terms of how air traffic is handled,” the DSB said. “This complexity entails certain risks for air traffic. Schiphol’s rapid growth is increasing that complexity further.”

Events recorded in 2014–16 include a pushback incident in November 2014; a clearance and takeoff of an Airbus A320 from a closed runway in June 2015; and a runway incursion in February 2016.

The DSB said factors behind the incidents include high workload and “capacity shortages” for air traffic controllers, and “not enough room to park aircraft.” Additional risks include traffic crossing the takeoff and landing runways; deviations from procedures to handle the traffic; and a large number of daily runway configuration changes—many of which are the result of “noise preferential flight operations” for communities. “All of this indicates that Schiphol is approaching the limits of its ability to handle air traffic safely within the current operational concept,” the DSB said.

Of concern to the DSB is that no single party takes responsibility for the integral safety of air traffic at and around the airport. While the Dutch government is ultimately responsible for safety at the airport, the DSB said that role has been delegated to “parties” that have not delivered “comprehensive, collective safety guarantees.”

Several of the recommendations are focused on the airport operator, Schiphol Group, and the nongovernmental air navigation services provider, Luchtverkeersleiding Nederland, or LVNL. Included are calls to develop “future-proofed” operational concepts for the airport, potentially including reducing runway configuration changes and complexity of the layout; and developing a “shared vision” on safety at Amsterdam Schiphol, including targets to be achieved.

The DSB is asking the Netherlands government to “flesh out the role of the party with final responsibility for safety at and around Schiphol,” in addition to actively monitoring safety; performing trend analyses; and carrying out “comprehensive assessments” of the safety impacts of potential changes due to the recommendations.

“This investigation makes it clear that further growth of Schiphol will require more than marginal adjustments to the existing policy,” said the DSB. “Indeed, this calls for a fundamental debate on the future of aviation in the Netherlands and on the options and limitations regarding Schiphol’s further growth.”

Please Log In or Register to post comments.


Commercial Aviation: Market Briefing

A subscription to Aviation Daily is required to access these stories.

 

 

Subscribe

Log In



Advertise with Us


Daily analysis on technology advances impacting the global aviation, aerospace defense industries.


PISCES





Sponsored Introduction Continue on to (or wait seconds) ×

Article source: http://aviationweek.com/awincommercial/who-charge-safety-amsterdam-schiphol

NOT FOR DISTRIBUTION IN OR INTO THE UNITED STATES

 

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities, nor is it calculated to invite any such offer or invitation. Neither this announcement nor any copy thereof may be taken into or distributed, directly or indirectly, in or into the United States (including its territories and dependencies, any State of the United States and the District of Columbia). In particular, this announcement does not constitute and is not an offer to sell or a solicitation of any offer to purchase or subscribe for securities in the United States or elsewhere. The securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended. Any public offering of securities to be made in the United States will only be made by means of a prospectus that may be obtained from the issuer or selling security holder and that contains detailed information about the issuer and management as well as financial statements. There is no intention to make a public offering of the securities referred to in this announcement in the United States.                                                                   

Almere, The Netherlands
April 24, 2017

ASM International N.V. (Euronext Amsterdam: ASM) (“ASMI”) today announces that it intends to sell a stake of 20 million shares of the total outstanding share capital in ASM Pacific Technology Ltd. (“ASMPT”) through a partial secondary share placement. Following the planned divestment ASMI will own approximately 34% of the shares in ASMPT.

ASMI views long-term value creation as very important. Regularly the Management Board reviews its strategy and, as part of that, the position it holds in ASMPT. The most recent review led to the conclusion that a further reduction of its shareholding of approximately 5% was justified. The Management Board remains of the opinion that, at this moment, a significant stake in ASMPT is of strategic value to ASMI.

Sale of partial stake in ASMPT and use of proceeds 

ASMI is proposing a reduction of its stake in ASMPT through an accelerated bookbuild offering to institutional investors of 20 million shares representing a stake of approximately 5% in ASMPT which is launching now. 

ASMI intends to use the proceeds for a new share buyback program. 

This new share buyback program will be in addition to the one which was announced on March 2, 2017. 

The Hongkong and Shanghai Banking Corporation Limited is acting as bookrunner for this transaction.  

Once the outcome of the offering has been established, ASMI will make a further public announcement. ASMI has agreed to a 180 day lock-up period.


About ASM International

ASM International NV, headquartered in Almere, the Netherlands, its subsidiaries and participations design and manufacture equipment and materials used to produce semiconductor devices. ASM International, its subsidiaries and participations provide production solutions for wafer processing (Front-end segment) as well as for assembly packaging and surface mount technology (Back-end segment) through facilities in the United States, Europe, Japan and Asia. ASM International’s common stock trades on the Euronext Amsterdam Stock Exchange (symbol ASM). For more information, visit ASMI’s website at www.asm.com

IMPORTANT NOTICES

The Hongkong and Shanghai Banking Corporation Limited (“HSBC”) is acting for the Company in relation to the transaction, will not regard any other person as a client in relation to the transaction and will not be responsible to anyone other than the Company for providing the protections afforded to clients of HSBC nor for providing advice to any such other person. Without prejudice to liability for fraud, HSBC, its affiliates and its and its and their respective directors, officers, employees and agents disclaim any liability to any such other person in connection with the transaction. 

This announcement is for information purposes only and, save as expressly set out herein, does not constitute an offer or invitation to underwrite, subscribe for or otherwise acquire or dispose of any securities or investment advice in any jurisdiction, including without limitation, the United Kingdom, the United States, Hong Kong, Australia, Canada, Japan, or South Africa. Persons needing advice should consult an independent financial adviser.

This announcement has been issued by and is the sole responsibility of the Company. No representation or warranty, express or implied, is or will be made as to, or in relation to, and no responsibility or liability is or will be accepted by the Bookrunner or by any of its respective affiliates or agents as to or in relation to, the accuracy or completeness of this announcement or any other written or oral information made available to or publicly available to any interested party or its advisers, and any liability therefor is expressly disclaimed.

The distribution of this announcement and the placing of the shares as set out in this announcement in certain jurisdictions may be restricted by law. No action has been taken by the Company or the Bookrunner that would permit an offering of such shares or possession or distribution of this announcement or any other offering or publicity material relating to such shares in any jurisdiction where action for that purpose is required.  Persons into whose possession this announcement comes are required by the Company and the Bookrunner to inform themselves about, and to observe, such restrictions.

This announcement does not constitute a prospectus or an offer or invitation to purchase securities. This announcement is only addressed to, and directed at, persons in member states of the European Economic Area (“EEA”) who are “qualified investors” within the meaning of Article 2(1)(e) of the Prospectus Directive (Directive 2003/71/EC) as amended by the 2010 PD Amending Directive (Directive 2010/73/EU), as and to the extent implemented in the relevant EEA member state, and any relevant implementing measure in the relevant member state.

In addition, in the United Kingdom, this announcement is not being distributed, nor has it been approved for the purposes of Section 21 of the Financial Services and Markets Act 2000 (“FSMA”), by a person authorised under FSMA and is directed only at, persons (i) who are persons having professional experience in matters relating to investments who fall within the definition of “investment professionals” in Article 19(5) of The Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended (the “Order”), or (ii) persons who are high net worth entities falling within Article 49(2)(a) to (d) of the Order, and other persons to whom it may lawfully be communicated (“relevant persons”). Under no circumstances should persons who are not relevant persons rely or act upon the contents of this announcement. Any investment or investment activity to which this announcement relates in the United Kingdom is available only to, and will be engaged only with, relevant persons.

This announcement does not constitute an invitation or offer to acquire, purchase or subscribe for securities, nor is it calculated to invite any such offer or invitation. Neither this announcement nor any copy thereof may be taken into or distributed, directly or indirectly, in or into the United States (including its territories and dependencies, any State of the United States and the District of Columbia). In particular, this announcement does not constitute and is not an offer to sell or a solicitation of any offer to purchase or subscribe for securities in the United States or elsewhere. The securities may not be offered or sold in the United States absent registration or an exemption from registration under the United States Securities Act of 1933, as amended. Any public offering of securities to be made in the United States will only be made by means of a prospectus that may be obtained from the issuer or selling security holder and that contains detailed information about the issuer and management as well as financial statements. There is no intention to make a public offering of the securities referred to in this announcement in the United States.

This announcement contains forward-looking statements. These statements are subject to a number of risks and uncertainties and actual results, and events could differ materially from those currently being anticipated as reflected in such forward-looking statements. The terms “expect”, “should be”, “will be” and similar expressions identify forward-looking statements. Factors which may cause future outcomes to differ from those foreseen in forward-looking statements include, but are not limited to: general economic and business conditions; demand for the Company’s products and services; competitive factors in the industries in which the Company operates; exchange rate fluctuations; legislative, fiscal and regulatory developments; political risks; terrorism, acts of war and pandemics; changes in law and legal interpretations affecting the Company’s intellectual property rights and internet communications; and the impact of technological change. Forward-looking statements speak only as of the date of such statements and, except as required by applicable law, the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise. The information contained in this announcement is subject to change without notice and neither the Company nor the Bookrunner assume any responsibility or obligation to update publicly or review any of the forward-looking statements contained herein.

Any indication in this announcement of the price at which ordinary shares have been bought or sold in the past cannot be relied upon as a guide to future performance.  No statement in this announcement is intended to be a profit forecast and no statement in this announcement should be interpreted to mean that earnings per share of the Company for the current or future financial years would necessarily match or exceed the historical published earnings per share of the Company.

The Bookrunner may participate in the Placement on a proprietary basis. 

CONTACT

Investor contact:

Victor Bareño

T: +31 88 100 8500

E: victor.bareno@asm.com

 

Media contact:

Ian Bickerton

T: +31 625 018 512 

Attachments:

http://www.globenewswire.com/NewsRoom/AttachmentNg/05ea2ea9-d8c7-41fe-948e-03e004d899c7

Article source: https://globenewswire.com/news-release/2017/04/24/970111/0/en/ASM-INTERNATIONAL-N-V-ANNOUNCES-INTENTION-TO-SELL-PARTIAL-STAKE-OF-APPROXIMATELY-5-IN-ASMPT.html

April 22, 2017, Amsterdam, The Netherlands: Results of the SARAH trial presented today demonstrate that SIRT resulted in median overall survival (OS) of 8.0 months compared to 9.9 months with sorafenib (p=0.179), in patients with locally advanced and inoperable hepatocellular carcinoma (HCC). The trial, presented at The International Liver Congress™ 2017 in Amsterdam, The Netherlands, further demonstrated that the cumulative incidence of radiologic progression in the liver as the first event was significantly lower in the SIRT group compared to the sorafenib group (p=0.014), and the response rate was significantly higher in the SIRT group compared to the sorafenib group (19.0% vs 11.6%, p=0.042). Both the side-effect profile and quality of life scores were significantly better over time in the SIRT group compared to the sorafenib group (p=0.005).

Liver cancer, or HCC, is the second most common cause of cancer-related deaths worldwide.1,2 HCC represents more than 90% of primary liver cancers and is a major global health problem.3 The prognosis for patients with advanced liver cancer is poor,2 and the multikinase inhibitor, sorafenib, is the only approved first-line systemic treatment.3 If patients are not tolerant or have contraindications for sorafenib therapy, there is currently no standard of care and patients lack effective treatment options.3 SIRT with yttrium-90 (Y-90) resin microspheres has shown promising anti-tumour results with a safe profile; further trials are needed to establish this treatment as a viable option for patients.3

“Patients with advanced or inoperable hepatocellular carcinoma have a poor prognosis, often with underlying cirrhosis, and the treatment option currently available, sorafenib, has a high level of toxicity. As cohort studies have demonstrated the efficacy of SIRT with Y-90 resin microspheres, we set out to compare the efficacy of this treatment versus the current standard of care,” said Prof Valérie Vilgrain, Hôpital Beaujon Service de Radiologie, Paris, France, and lead author of the study. “While SIRT demonstrated significantly reduced side effects, better quality of life, higher response rates and more effectively controlled tumour progression in the liver, the overall survival of patients was not higher than in the sorafenib group. Nonetheless, this study provides evidence that SIRT may be a better-tolerated alternative for managing this complex and difficult-to-treat disease, deserving further evaluation.”

The SARAH trial was a randomised, controlled, open-label, multicentre investigator initiated Phase 3 trial. Patients with locally advanced or inoperable HCC, who did not respond to other treatments or had two failed rounds of transarterial chemoembolisation, were randomised to SIRT with Y-90 resin microspheres, or oral sorafenib 400 mg twice daily. The primary endpoint of the study was OS and secondary endpoints included progression-free survival (PFS), time to radiological progression at any site and in the liver as the first event, tumour response, quality of life, and safety and toxicity.

There were 459 patients from 25 French clinical centres included in the study, 237 of whom received SIRT. Median PFS was 4.1 months and 3.7 months in the SIRT and sorafenib groups, respectively (p=0.765). Cumulative incidence of radiological progression at any site did not differ in either group (p=0.256). Overall, there were 1,297 and 2,837 treatment-related adverse events (AEs) including 230 and 411 grade ?3, in the SIRT and sorafenib groups, respectively. The number of patients with at least one treatment-related adverse event was 173 (76.5%) and 203 (94.0%), (p

“The SARAH trial is the first reported randomised controlled trial evaluating the survival benefit of SIRT in locally advanced HCC compared to sorafenib. SIRT was found to be safe, but regrettably the study failed meet the primary endpoint and SIRT did not show an overall survival superior to sorafenib. Further trials are needed to establish this treatment as a viable option for patients,” said Prof Alejandro Forner, BCLC group, Liver Unit, Hospital Clinic Barcelona, Spain and EASL Governing Board Member.

###

Yttrium-90 resin microspheres

Y-90 resin microspheres are miniscule radioactive ‘beads’ that are used in SIRT. They contain the radioactive component yttrium-90. These microspheres are injected in huge quantities into the liver tumours, where they become stuck in the small blood vessels that are in and around the tumours. The microspheres then emit high doses of radiation, which enable doctors to deliver up to 40 times more radiation to the liver tumours than would be possible using standard radiation therapy, all while sparing surrounding healthy tissue.4

About The International Liver Congress™

This annual congress is the biggest event in the EASL calendar, attracting scientific and medical experts from around the world to learn about the latest in liver research. Attending specialists present, share, debate and conclude on the latest science and research in hepatology, working to enhance the treatment and management of liver disease in clinical practice. This year, the congress is expected to attract approximately 10,000 delegates from all corners of the globe. The International Liver Congress™ 2017 will take place from April 19 – 23, at the RAI Amsterdam, Amsterdam, The Netherlands.

About The European Association for the Study of the Liver (EASL)

Since its foundation in 1966, this not-for-profit organisation has grown to over 4,000 members from all over the world, including many of the leading hepatologists in Europe and beyond. EASL is the leading liver association in Europe, having evolved into a major European Association with international influence, with an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.

Contact

For more information, please contact the ILC Press Office at:

  • Email: ILCpressoffice@ruderfinn.co.uk
  • Telephone: +44 (0)7841 009 252

Onsite location reference

Session title: General session III and award ceremony II

Time, date and location of session: 10:00 – 12:00, Saturday 22 April, Hall 5

Presenter: Valérie Vilgrain, France

Abstract: SARAH: a randomised controlled trial comparing efficacy and safety of selective internal radiation therapy (with yttrium-90 microspheres) and sorafenib in patients with locally advanced hepatocellular carcinoma (GS012), 10:00 – 10:15

Author disclosures

Speaker fees: Guerbet, SIRTEX, Supersonic, Toshiba. SIRTEX: Funding of SARAH trial. Guerbet: Study Investigator.

References

1 World Health Organization. Cancer. Available from: http://www.who.int/mediacentre/factsheets/fs297/en/. Last accessed: April 2017.

2 World Health Organization. GLOBOCAN 2012: Estimated cancer incidence, mortality and prevalence worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx. Last accessed: April 2017.

3 EASL-EORTC Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943.

4 Sirtex Medical Liminted. About SIR-Spheres microspheres. Available from: http://www.sirtex.com/us/patients/about-sir-spheres-microspheres/. Last accessed: April 2017.

Article source: https://www.eurekalert.org/pub_releases/2017-04/eaft-sib041217.php